<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572191</url>
  </required_header>
  <id_info>
    <org_study_id>anterior STEMI</org_study_id>
    <nct_id>NCT04572191</nct_id>
  </id_info>
  <brief_title>Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention</brief_title>
  <acronym>STEMI</acronym>
  <official_title>Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ceramide level as a predictor of outcomes in patients of anterior myocardial infarction&#xD;
      undergoing primary Coronary intervention&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ceramides are a family of lipid molecules that are found in high concentrations within cell&#xD;
      membranes and play a key role in a variety of physiological functions including apoptosis,&#xD;
      cell growth, cell adhesion and plasma membrane integrity maintenance.(1)&#xD;
&#xD;
      All tissues can synthesize ceramides de novo from saturated fats and sphingosine.(2) the (&#xD;
      LDL ) Present in atherosclerotic plaque is rich in ceramide and contain 10 - 50 fold higher&#xD;
      content of ceramide when compared with plasma LDL .(3)&#xD;
&#xD;
      Ceramide (d18:1/16:0) is associated with the fraction of necrotic core tissue and lipid core&#xD;
      burden in coronary atherosclerosis.(4) Previous clinical research found that circulating&#xD;
      ceramides are elevated in patients with hypertension,(5) obesity (6 - 7) and type II diabetes&#xD;
      mellitus.&#xD;
&#xD;
      Previous clinical research found that elevated ceramide plasma concentrations are associated&#xD;
      with coronary plaque vulnerability evaluated by intravascular ultrasound .&#xD;
&#xD;
      virtual Recent studies showed targeted profiling of ceramides predicted short-term and&#xD;
      long-term major adverse cardiac events.&#xD;
&#xD;
      Plasma ceramide level is also positively associated with the levels of total cholesterol. [8&#xD;
      - 9] The plasma ceramides that have been studied as high-risk factors are Cer (d18:1/16:0),&#xD;
      Cer (d18:1/18:0) and Cer (d18:1/24:1) and the ratios of these ceramides to Cer (d18:1/24:0)&#xD;
      [10 - 11].&#xD;
&#xD;
      However, it is tempting to speculate that ceramides are associated with plaque vulnerability&#xD;
      as they are known to fuel many central atherosclerosis processes including lipoprotein&#xD;
      aggregation and uptake, inflammation, superoxide anion production, andapoptosis 12 - 13 - 14&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to detect early &amp; mid -term MACE complication in anterior STEMI patients undergoing PPCI &amp; their relation with ceramide level in these patients</measure>
    <time_frame>BASELINE</time_frame>
    <description>to detect early &amp; mid -term MACE complication in anterior STEMI patients undergoing PPCI &amp; their relation with ceramide level in these patients</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anterior STEMI</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CERAMIDE LEVEL IN BLOOD</intervention_name>
    <description>BY ELISA ASSAY TO DETECT CERAMIDE LEVEL IN BLOOD IN ANTERIOR STEMI PATIENTS</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ALL PATIENTS COMPLAING OF ANTERIOR STEMI &amp; UNDERENTPRIMARY PCI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1- Subjects with anterior STEMI according to ESC guidelines 2017 . 2. Subjects&#xD;
             undergoing PPCI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous PCI. Patients with previous CABG. Patients with TIMI flow less&#xD;
             than II. Patients with residual stenosis more than 70 % in major artery. Cardiogenic&#xD;
             shock.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mohamed abdel - ghani, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>esraa RESIDENT sayed</last_name>
    <phone>01060558484</phone>
    <email>esraa.sayed3369@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>salwa Rushdy, professor</last_name>
    <phone>01223971267</phone>
    <email>Salwademitry@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Esraa Sayed Hamed</name>
      <address>
        <city>Assiut</city>
        <zip>23123</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>salwa Rushdy, professor</last_name>
      <phone>01223971267</phone>
      <email>Salwademitry@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>mohamed abdel - ghani, professor</last_name>
      <phone>01025880990</phone>
      <email>m-koriem2004@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Tu C, Xie L, Wang Z, Zhang L, Wu H, Ni W, Li C, Li L, Zeng Y. Association between ceramides and coronary artery stenosis in patients with coronary artery disease. Lipids Health Dis. 2020 Jun 25;19(1):151. doi: 10.1186/s12944-020-01329-0.</citation>
    <PMID>32586390</PMID>
  </reference>
  <reference>
    <citation>Pan W, Li L, Sun M, Wang C, Fang S, Yu B. Plasma ceramides are associated with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2020 Dec 1;320:155-160. doi: 10.1016/j.ijcard.2020.08.010. Epub 2020 Aug 12.</citation>
    <PMID>32800902</PMID>
  </reference>
  <reference>
    <citation>Mantovani A, Bonapace S, Lunardi G, Canali G, Dugo C, Vinco G, Calabria S, Barbieri E, Laaksonen R, Bonnet F, Byrne CD, Targher G. Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. Diabetes Metab. 2020 Apr;46(2):150-157. doi: 10.1016/j.diabet.2019.07.006. Epub 2019 Aug 3.</citation>
    <PMID>31386900</PMID>
  </reference>
  <reference>
    <citation>Tu CC, Wan BY, Zhao XL, Li CX, Wu HM, Zhang LL, Li L, Zeng Y. [Value of ceramide in the diagnosis and risk prediction of coronary artery disease]. Zhonghua Yi Xue Za Zhi. 2019 Oct 22;99(39):3089-3092. doi: 10.3760/cma.j.issn.0376-2491.2019.39.010. Chinese.</citation>
    <PMID>31648453</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>esraa sayed hamed Ahmed</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

